Pepgen inc. provides update on planned initiation of phase 1 study of pgn-edodm1 in myotonic dystrophy type 1

Boston, june 13, 2023 (globe newswire) -- pepgen inc. (nasdaq: pepg), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that while it awaits receipt of an official clinical hold letter from the u.s. food and drug administration (fda), the company is withdrawing its prior guidance with respect to the timeline for initiating a phase 1 study of pgn-edodm1 in patients with myotonic dystrophy type 1 (dm1) in the first half of 2023 in any geography.
PEPG Ratings Summary
PEPG Quant Ranking